Edgewise Therapeutics (NASDAQ:EWTX)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Read More
Trailing Twelve Months EPS: ($1.55)
2024 EPS Estimate: ($1.48)
2025 EPS Estimate: ($1.83)
- Current Stock Price
- $27.65
- Consensus Rating
- Buy
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $35.00 (26.6% Upside)
